Share Price, page-6378

I think one of the key purposes of 'capping' or 'price compression' is to keep traders out of the stock. The mute button has been hit on each piece of news beginning with the FDA approval: price jumps then it is taken in hand, controlled and walked back down, muting the response and allowing the impression that maybe what we thought was good news, wasn't really, not with the way the 'market is reacting'. The very goal is to undermine the narrative, seed doubt by making the SP go backwards and create a lack of interest while accumulation occurs.

So you are right Baldwix, it is the Manipulator's Design you are picking up on. Retail investors cannot act in any kind of organized way unless it's loosely in appreciation of good fundamental news moments, the big players have 'organization', call it algorithms and cross trading, add institutional shorting, they have the tools to put the price where they want it within reason. But none of that should threaten an investor's common sense view of how the company is performing and in Neuren's case that is very, very well, for an Australian pharma.